Bioresorbable vascular scaffolds : the way forward? by Vella, Claire
With the sheer breadth of emerging evidence in the field, cardiology is remarkable in its ability to evolve and grow. The Malta Cardiac Society Conference in October 2015 
discussed many advances in the specialty, but especially exciting 
was the announcement of the introduction of bioresorbable 
vascular scaffolds during percutaneous coronary interventions 
(PCI) carried out in Malta. 
thE story so far
When the advent of balloon angioplasty revolutionized 
treatment for coronary artery disease in 1977, patients who 
could previously only be treated with bypass surgery began to 
enjoy decreased morbidity and mortality rates. However, balloon 
angioplasty had significant early and late restenosis risk1 which 
limited its long-term benefit. This led to the development of 
bare-metal stenting, which improved early failure rates but did 
not result in comparative improvement in long-term restenosis 
rates.2
Drug-eluting stents (DES) were a big step forward in terms 
of late restenosis risk. The landmark RAVEL study in 2002 
showed significantly lower late luminal loss in sirolimus-coated 
stents compared to bare-metal stents, with a major cardiac 
adverse event (MACE) rate of 5.8% in the drug-eluting stent 
group compared to 28.8% in the bare-metal stent group.3
However, DES have been fraught with difficulties that belie 
their initial reception as life-saving for patients with coronary 
artery disease. Their comparatively rigid metal design has been 
shown to alter normal coronary flow dynamics due to impaired 
vasoconstriction. Moreover, the exposed metal framework in 
incompletely endothelialised stents is thought to lead to chronic 
inflammation which in turn leads to more delayed restenosis 
rates, with 10% needing repeat revascularization at 5 years.4
thE nEW Kids on thE blocK
Bioresorbable vascular scaffolds (BVSs) were born out of a 
need for better  reperfusion techniques. Most models are made 
out of a flexible braided mesh of poly-L-lactic acid polymer 
(PLLA) or bioresorbable metal alloys coated with everolimus, 
and are reabsorbed completely within 5 years after deployment.5 
The temporary nature of scaffolds is thought to confer a 
significant advantage in terms of restenosis rates as scaffolds 
are designed to be completely endothelialised before dissolving, 
leading to reduced local inflammation and restenosis while the 
artery slowly heals. The ABSORB-STEMI TROFI II clinical 
trial, published in September 2015, compared 6-month healing 
response rates between DES and BVS in patients undergoing 
primary PCI in ST-elevation myocardial infarction. Results 
showed that there was no difference in arterial healing 
between both groups at 6 months, proving non-inferiority of 
bioresorbable scaffolds in this regard.6 
Moreover, the ABSORB-III clinical trial is currently 
underway, designed to prove superiority of BVS compared to 
conventional everolimus-eluting metal stents in elective PCIs 
for stable and unstable myocardial ischemia.7 This large-scale, 
BIoresorBaBle Vascular  
scaffolds: the way forward?
heart matters
clairE VElla
Seretide® Evohaler®
50 mcg from 4 years3
Seretide® Diskus®
100 mcg from 4 years4
Help Poppy by prescribing Seretide
Seretide is the only ICS/LABA proven to achieve
guideline-deﬁ ned asthma control in children2
Safety Information
Very common side effects: Headache and nasopharyngitis. 
Common side effects: Candidiasis of mouth and throat, pneumonia, bronchitis, hypokalaemia and hoarseness/dysphonia
Special warnings and precautions for use: Systemic effects may occur with any inhaled corticosteroid, particularly at high doses 
prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. 
It is important that patients are reviewed regularly and the dose of inhaled corticosteroid is reduced to the lowest dose at which effective 
control of asthma is maintained. Monitor height of children on prolonged inhaled steroid therapy.
Date of Preparation: January 2015 ZINC CODE: MLT_GIB/SFC/0002/15
References
1.  Wildhaber, J et al. Pediatr. Pulmonol 2012; 47:346–357.
2.  DeBlic J et al. Pediatr Allergy Immunol 2009: 20:763–771
3.  Seretide Evohaler ( uticasone propionate/salmeterol xinafoate) 
Summary of Product Characteristics,  Allen & Hanburys Ltd. October 2014.
4.  Seretide Accuhaler ( uticasone propionate/salmeterol xinafoate)
Summary of Product Characteristics,  Allen & Hanburys Ltd. October 2014.
Seretide™ (salmeterol xinafoate and fluticasone propionate) 
Kindly refer to full Summary of Product Characteristics (SPC) before prescribing.
Abridged prescribing information. Presentations: For Malta and Gibraltar: Seretide Diskus – Each dose 
provides 50 microgram salmeterol xinafoate and 100 microgram, 250 microgram or 500 microgram respectively 
of fluticasone propionate. Seretide 50 Evohaler - Each dose provides 25 microgram salmeterol xinafoate and 
50 microgram of fluticasone propionate. For Gibraltar only: Seretide 125, 250 Evohaler: Each dose provides 25 microgram 
salmeterol xinafoate and 125 microgram or 250 microgram of fluticasone propionate. Therapeutic Indications: 
For Malta and Gibraltar: Seretide Diskus and Evohaler: is indicated in the regular treatment of asthma where use of 
a combination (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate. Seretide Diskus is indicated for 
the symptomatic treatment of patients with COPD with a FEV1<60% predicted normal (pre-bronchodilator) and a 
history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. Seretide 
50 Evohaler is used in patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled 
short acting beta-2-agonist or patients already adequately controlled on both inhaled corticosteroid and long-
acting beta-2-agonist. For Gibraltar only: Seretide 125, 250 Evohaler: is indicated in the regular treatment of asthma 
where use of a combination (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate. Used in patients 
not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short acting beta-2-agonist or 
patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. Dosage and 
administration: Seretide is for inhalation use only. Seretide Diskus: Asthma – Adults and adolescents 12 years 
and over: one puff twice daily of Seretide 100 or Seretide 250 or Seretide 500 (each containing 50 mcg of salmeterol 
xinafoate and 100 mcg, 250 mcg or 500 mcg respectively of fluticasone propionate). Patients should be given the 
strength of Seretide containing the appropriate, lowest fluticasone propionate dosage for the severity of their 
disease. A short term trial of Seretide may be considered as initial maintenance therapy in adults or adolescents 
with moderate persistent asthma (defined as patients with daily symptoms, daily rescue use and moderate to severe 
airflow limitation) for whom rapid control of asthma is essential. In these cases, the recommended initial dose is 
one inhalation of 50 micrograms salmeterol and 100 micrograms fluticasone propionate twice daily. Once control of 
asthma is attained treatment should be reviewed and consideration given as to whether patients should be stepped 
down to an inhaled corticosteroid alone. Regular review of patients as treatment is stepped down is important. 
Seretide is not intended for the initial management of mild asthma. Seretide 50/100 micrograms strength is not 
appropriate in adults and children with severe asthma. Children 4-11 years: Seretide 100 Diskus (50 mcg salmeterol 
and 100 mcg fluticasone propionate) – one puff twice daily. Seretide Diskus: COPD: Seretide 500 Diskus (50 mcg 
of salmeterol xinafoate and 500 mcg fluticasone propionate) – one puff twice daily. Seretide 50 Evohaler: Adults 
and children 4 years and older: Two inhalations twice daily. For Gibraltar only: Seretide 125, 250 Evohaler: Adults 
and adolescents 12 years and older: Two inhalations twice daily. Contra-indications: Hypersensitivity. Warnings 
and Precautions: Seretide should not be used to treat acute asthma symptoms for which a fast- and short-acting 
bronchodilator is required. Patients should not be initiated on Seretide during an exacerbation, or if they have 
significantly worsening or acutely deteriorating asthma. Serious asthma-related events and exacerbations can occur 
during Seretide therapy; sudden and progressive deterioration in control or increased use of bronchodilator therapy 
warrants urgent medical assessment especially in patients of African-American origin (SMART). As with all inhaled 
medication containing corticosteroids, Seretide should be administered with caution in patients with pulmonary 
tuberculosis, severe cardiovascular disorders, including heart rhythm abnormalities, diabetes mellitus, untreated 
hypokalaemia/patients predisposed to hypokalaemia or thyrotoxicosis. In case of paradoxical bronchospasm 
discontinue Seretide, assess patient and give alternative therapy if necessary. Systemic effects may occur with any 
inhaled corticosteroid, particularly at high doses prescribed for long periods, but are less likely than with oral 
steroids. It is important, therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is 
reduced to the lowest dose at which effective control of asthma is maintained. Prolonged treatment of patients 
with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crises. Rarely, a range 
of psychological or behavioural effects such as psychomotor hyperactivity, sleep disorders, anxiety, depression or 
aggression (particularly in children) may develop on prolonged use. Monitor height of children on prolonged inhaled 
steroid therapy. Transfer from oral steroids: Special care needed. Monitor adrenal function. Consider appropriate 
steroid therapy during periods of stress or elective surgery. Ritonavir can greatly increase the concentration of 
fluticasone propionate in plasma, therefore avoid concomitant use. There is also an increased risk of systemic side 
effects with other potent CYP3A inhibitors. There was an increased reporting of lower respiratory tract infections 
(particularly pneumonia and bronchitis) in the TORCH study in patients with COPD receiving Seretide compared 
with placebo; older patients, patients with a lower body mass index (<25kg/m2) and patients with very severe 
disease (FEV1<30% predicted) were at greatest risk of developing pneumonia regardless of treatment. Concomitant 
use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may lead to an increase 
in the incidence of systemic effects (e.g. prolongation in the QTc interval and palpitations). Concomitant treatment 
with ketoconazole or other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the 
potentially increased risk of systemic side effects of salmeterol treatment. Drug Interactions: Avoid beta-blockers. 
Concomitant use with other beta-adrenergic containing drugs can have a potentially additive effect. Potent CYP3A4 
inhibitors: Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 mcg inhaled twice daily) 
resulted in a significant increase in plasma salmeterol exposure which may lead to an increase in the incidence of 
other systemic effects of salmeterol treatment (e.g. prolongation of QTc interval and palpitations) compared with 
salmeterol or ketoconazole treatment alone. The concomitant administration of ketoconazole should be avoided, 
unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment. There 
is likely to be a similar risk of interaction with other potent CYP3A4 inhibitors (e.g. itraconazole, telithromycin, 
ritonavir). Pregnancy and Lactation: Experience limited. Balance risks against benefits. Undesirable effects: 
Very Common/Common - candidiasis of mouth and throat, pneumonia, bronchitis, hypokalaemia, headache, hoarseness/
dysphonia, throat irritation (uncommon with Seretide 50 Evohaler), nasopharyngitis, sinusitis, contusions, traumatic 
fractures, arthralgia and myalgia, muscle cramps (uncommon with Seretide 50 Evohaler). See SPC for information 
on all adverse events. Overdose: due to Salmeterol: tremor, headache, tachycardia; due to Fluticasone propionate: 
temporary adrenal suppression. 
MA Holder (Malta): GlaxoSmithKline (Ireland) Ltd. Trading as: Allen & Hanburys Ltd. MA Numbers (Malta): 
Seretide Diskus: MA 192/00901-3; Seretide 50 Evohaler: AA 192/00904. Legal category: POM. Not all pack sizes may 
be marketed. Date of revision of text: August 2013. 
In order to ensure that this product information reflects the most up-to-date clinical and 
post-marketing surveillance data, please always refer to the latest Summary of Product 
Characteristics which is available from GlaxoSmithKline (Malta) Ltd (Tel: +356 21238131) 
REPORTING ADVERSE EVENTS (AEs): 
If you become aware of any AEs, medication errors and/or use during pregnancy in association 
with GSK products, please report the event promptly to: GSK (Malta) Limited, 1, De la Cruz Avenue, 
Qormi QRM 2458, Malta (Tel: +356 21238131) or e-mail: mt.info@gsk.com
Malta: any suspected AEs and medication errors can also be reported via the national Adverse 
Drug Reactions (ADRs) reporting system: 
Report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal and posted to the Malta 
Medicines Authority, Post-licensing Directorate, 203, Level 3, Rue D’Argens, Gżira GŻR 1368, MALTA, or sent 
by email to postlicensing.medicinesauthority@gov.mt 
Gibraltar: any suspected AEs and medication errors can also be reported via the UK regulatory 
authority (MHRA): https://yellowcard.mhra.gov.uk/
Poppy is 50% less 
likely to wake at night 
when using Seretide 
compared to baseline2
59% of  children wake at
night due to their asthma1
Seretide-LP-Night-GSKDC-PT-ADI-2015-0034_D1.indd   2 1/23/2015   9:53:02 PM
19
multicenter randomized trial aims to determine the difference 
between BVS and DES groups with a primary endpoint of target 
lesion failure, defined as restenosis, myocardial infarction in 
the relevant territory, and cardiac death. The first results are 
expected next year, but are expected to show optimistic findings 
with respect to BVS.
bVs and antiplatElEt thErapy
The use of dual antiplatelet therapy with aspirin and a 
P2Y12-receptor inhibitors, such as clopidogrel and prasugrel, 
has long gone hand in hand with cardiac stenting in order to 
prevent restenosis. With the finite lifespan of scaffolds, one could 
postulate that antiplatelet therapy may possibly be stopped at an 
earlier stage, especially in patients with high bleeding risk. 
However, even with their short lifespan and superior 
endothelialisation, there is still a risk of thrombosis with 
scaffolds, especially if they have not been properly implanted.8  
Furthermore, early discontinuation or absence of antiplatelet 
therapy has been shown to be associated with scaffold 
thrombosis. 
The current consensus is that at least 6-12 months of dual 
antiplatelet therapy are needed after BVS insertion,9 followed by 
lifelong aspirin. However, the kind of device used together with 
patient preference and bleeding risk play an important role in 
choice of therapy.10 
liMitations and gaps in EVidEncE
While BVS is being touted in some circles as the future of 
PCI, the reality is that the technology is far too young for us 
to really tell what will happen. Even though evidence is slowly 
starting to mount and the picture is becoming clearer with 
respect to short- and long-term advantages and disadvantages 
of the devices, there are still lacunae  in our knowledge.
An obvious presumed limitation is the use of more fragile 
scaffolds in tough, calcified arteries as opposed to metal stents 
– evidence regarding efficacy in this regard is particularly 
limited. 
There is also a lack of large studies on outcomes in patients 
who need repeated PCI.  Scaffolds would in theory lend 
themselves better to situations where repeat revascularization 
is needed, avoiding the “full metal jacket” that is unfortunately 
all too common in patients with uncontrolled ischaemic heart 
disease. 
Although studies have mostly focused on the insertion of 
scaffolds in ST segment elevation MI and chronic ischaemic 
heart disease, patients with chronic total occlusion have mostly 
been sidelined. There are some small, single-centre studies 
that indicate that BVS shows promising results in chronic total 
occlusion,11 but there is a glaring lack of robust multicenter 
randomized controlled trials.
thE Way forWard
BVS are incredibly promising, but there appear to be 
limitations to their use. The 2014 European Society of 
Cardiology guidelines on Myocardial Revascularisation12 
do not give more than a brief overview about scaffolds and 
are cautious about indications for use, pending randomized 
controlled trials. Certainly, however, the introduction of 
bioresorbable scaffolds in the Cardiac Catheterisation Suite 
in Malta marks the beginning of a new chapter in PCI and as 
newer evidence emerges, we will see exactly where these novel 
devices fit in the bigger picture.  rEf
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